166 related articles for article (PubMed ID: 19229603)
1. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial study design and rationale.
Dominguez-Rodriguez A; Fard SS; Abreu-Gonzalez P; Bosa-Ojeda F; Consuegra-Sanchez L; Jiménez-Sosa A; Grande AS; Kaski JC
Cardiovasc Drugs Ther; 2009 Jun; 23(3):243-7. PubMed ID: 19229603
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
[TBL] [Abstract][Full Text] [Related]
4. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696].
Ostadal P; Alan D; Hajek P; Vejvoda J; Mates M; Blasko P; Veselka J; Kvapil M; Kettner J; Wiendl M; Aschermann O; Slaby J; Nemecek E; Holm F; Rac M; Macek M; Cepova J
Curr Control Trials Cardiovasc Med; 2005 Mar; 6(1):4. PubMed ID: 15790413
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial).
Ostadal P; Alan D; Vejvoda J; Kukacka J; Macek M; Hajek P; Mates M; Kvapil M; Kettner J; Wiendl M; Aschermann O; Slaby J; Holm F; Telekes P; Horak D; Blasko P; Zemanek D; Veselka J; Cepova J
Trials; 2010 May; 11():61. PubMed ID: 20500832
[TBL] [Abstract][Full Text] [Related]
7. Low-dose
Sriranjan R; Zhao TX; Tarkin J; Hubsch A; Helmy J; Vamvaka E; Jalaludeen N; Bond S; Hoole SP; Knott P; Buckenham S; Warnes V; Bird N; Cheow H; Templin H; Cacciottolo P; Rudd JHF; Mallat Z; Cheriyan J
BMJ Open; 2022 Oct; 12(10):e062602. PubMed ID: 36207050
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent changes of hs-CRP serum concentration in patients with non-ST elevation acute coronary syndrome.
Jahn J; Hellmann I; Maass M; Giannitsis E; Dalhoff K; Katus HA
Herz; 2004 Dec; 29(8):795-801. PubMed ID: 15599677
[TBL] [Abstract][Full Text] [Related]
9. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Tardif JC; McMurray JJ; Klug E; Small R; Schumi J; Choi J; Cooper J; Scott R; Lewis EF; L'Allier PL; Pfeffer MA;
Lancet; 2008 May; 371(9626):1761-8. PubMed ID: 18502300
[TBL] [Abstract][Full Text] [Related]
10. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
11. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
[TBL] [Abstract][Full Text] [Related]
12. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
13. Clinical correlation of multiple biomarkers for risk assessment in patients with acute coronary syndrome.
Narain VS; Gupta N; Sethi R; Puri A; Dwivedi SK; Saran RK; Puri VK
Indian Heart J; 2008; 60(6):536-42. PubMed ID: 19276492
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
[TBL] [Abstract][Full Text] [Related]
16. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
[TBL] [Abstract][Full Text] [Related]
17. [Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events].
Díaz CJ; Núñez AC; Flores MI; Arcaute HD; Archondo T
Arch Cardiol Mex; 2006; 76(4):366-75. PubMed ID: 17315612
[TBL] [Abstract][Full Text] [Related]
18. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
Filipovský J
Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]).
Lim P; Moutereau S; Simon T; Gallet R; Probst V; Ferrieres J; Gueret P; Danchin N
Am J Cardiol; 2013 Jan; 111(1):31-7. PubMed ID: 23062316
[TBL] [Abstract][Full Text] [Related]
20. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
